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Most of the studies characterizing DNA methylation patterns have been restricted to particular genomic loci in a limited
number of human samples and pathological conditions. Herein, we present a compromise between an extremely com-
prehensive study of a human sample population with an intermediate level of resolution of CpGs at the genomic level. We
obtained a DNA methylation fingerprint of 1628 human samples in which we interrogated 1505 CpG sites. The DNA
methylation patterns revealed show this epigenetic mark to be critical in tissue-type definition and stemness, particularly
around transcription start sites that are not within a CpG island. For disease, the generated DNAmethylation fingerprints
show that, during tumorigenesis, human cancer cells underwent a progressive gain of promoter CpG-island hyper-
methylation and a loss of CpG methylation in non-CpG-island promoters. Although transformed cells are those in which
DNA methylation disruption is more obvious, we observed that other common human diseases, such as neurological and
autoimmune disorders, had their own distinct DNA methylation profiles. Most importantly, we provide proof of prin-
ciple that the DNA methylation fingerprints obtained might be useful for translational purposes by showing that we are
able to identify the tumor type origin of cancers of unknown primary origin (CUPs). Thus, the DNAmethylation patterns
identified across the largest spectrum of samples, tissues, and diseases reported to date constitute a baseline for developing
higher-resolution DNA methylation maps and provide important clues concerning the contribution of CpG methylation
to tissue identity and its changes in the most prevalent human diseases.
[Supplemental material is available for this article.]
Epigenetics encompasses a large number of mechanisms underly-
ing embryonic development, differentiation, and cell identity, in-
cluding DNA methylation and histone modifications (Bernstein
et al. 2007; Hemberger et al. 2009). The existence of distinct epi-
genomes might explain why the same genotypes generate different
phenotypes, such as those seen inAgoutimice (Michaud et al. 1994),
cloned animals (Humpherys et al. 2001), and monozygotic twins
(Fraga et al. 2005; Kaminsky et al. 2009). Most importantly, epige-
netic alterations are increasingly recognized as being involved in
human diseases (Das et al. 2009), such as cancer (Jones and Baylin
2007; Esteller 2008) and imprinting (Feinberg 2007), neurological
(Urdinguio et al. 2009), cardiovascular (Gluckman et al. 2009), and
autoimmune (Richardson 2007) disorders, among others. For the
first time, it is possible to define whole epigenomes, which represent
all epigenetic marks in a given cell type, thanks to the development
of powerful new genomics technologies (Bernstein et al. 2007;
Esteller 2007; Jones and Baylin 2007; Bonetta 2008; Lister and Ecker
2009). Furthermore, coordinated epigenomic projects are starting to
be launched (Jones et al. 2008; Abbot 2010).
One of the earliest studied epigenetic marks in eukaryotes is
cytosine DNA methylation, which acts as a stably inherited mod-
ification affecting gene activity and cellular biology. Determining
the complete DNA methylome entails describing all the methyl-
ated nucleotides in an organism. The gold standard technique for
analyzing the methylation state of individual cytosines is bisulfite
sequencing in which unmethylated cytosines are converted to
uracils and read as thymines, while methylated cytosines are pro-
tected from conversion. Bisulfite sequencing yields precise nucle-
otide resolution data, but this method has been limited to rela-
tively small genome coverage (Rakyan et al. 2004; Eckhardt et al.
2006; Frigola et al. 2006; Zhang et al. 2009), although it has proved
useful for analyzing viral DNA methylomes (Fernandez et al.
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2009). Alternative approaches involve the isolation of methylated
fractions of the genome by methylation-sensitive restriction
(Lippman et al. 2005; Irizarry et al. 2008), immunoprecipitation
with a methylcytosine (Weber et al. 2005; Keshet et al. 2006; Weber
et al. 2007; Down et al. 2008) or methyl-CpG binding domain an-
tibody (Ballestar et al. 2003; Rauch et al. 2009), combined with hy-
bridization to genomic microarrays or ultrasequencing. This is ex-
emplified by the recentDNAmethylation analyses of theArabidopsis
genome (Zhang et al. 2006; Vaughn et al. 2007; Zilberman et al.
2007), which are further expanded by using sequencing-by-synthesis
(MethylC-Seq) technology (Lister et al. 2008) and shotgun bisulfite
genomic sequencing (Cokus et al. 2008). In representing mouse plu-
ripotent and differentiated cells, bisulfite sequencing has covered
roughly 1 million distinct CpG dinucleotides (4.8% of all CpGs)
(Meissner et al. 2008), and two human cell lines (one each from
embryonic stem cells and fetal fibroblasts) have been analyzed using
MethylC-Seq, including 94% of the cytosines in the genome (Lister
et al. 2009). Using whole-genome bisulfite sequencing, the DNA
methylome analysis of peripheral blood mononuclear cells from
a single case has also been recently reported (Li et al. 2010).
Only a small number of base-resolution DNA methylomes
have been described so far. Nevertheless, even with the enormous
advantages that genetic sequencing has over DNA methylation
characterization with respect to time and technology, very few full
genomes have been reported, either. From the genetic standpoint,
this current shortage of information is being tackled through the
development of efforts such as the 1000 Genomes Project (Kuehn
2008; Siva 2008) or by genome-wide association scan (GWAS)
studies in which an association with a phenotype or a disease can
be established if we limit the number of nucleotides assessed and
thus the extent of coverage of the genome (Cantor et al. 2010;
Ku et al. 2010). We decided to combine these two approaches—
extremely extensive analyses of hundreds of normal and disease-
associated cells and tissues with intermediate coverage of CpG
dinucleotides—to obtain a DNA methylation fingerprint of 1628
human samples corresponding to healthy individuals and in those
affected by the diseases most commonly associated with death in
the Western world, such as cancer, neurological disorders, and
cardiovascular disease.
Results
Description of 1628 samples and analysis of 1505 CpG sites
We first studied the genomic DNA from 1628 human samples
corresponding to 424 normal tissues (180 leukocytes, 97 colon
mucosa, and 227 other normal samples), 1054 tumorigenic sam-
ples (premalignant lesions, primary tumors, and metastases), and
150 non-cancerous disorders, such as brain lesions fromAlzheimer’s
disease, dementia with Lewy bodies, aortic atherosclerotic lesions,
myopathies, and autoimmune disorders. Supplemental Table 1
shows the complete list of samples studied. The age of donors
ranged from 6 mo to 102 yr, with an average age of 57 yr. Forty
percent (n = 648) were men, and 38% (n = 623) were women, the
gender of the remaining 22% (n = 357) not being known. Eighty-
seven percent (n = 1421) of the samples were from European vol-
unteers and patients, while 4% (n = 59) and 2% (n = 36) were from
Asian and North American populations, respectively; the origin was
not known for 7% (n = 112) of cases. Finally, 93% (n = 1512) of the
samples were primary tissues obtained at the time of the clinically
indicated procedures, while 7% (n = 116) were obtained from es-
tablished cell lines. Supplemental Figure 1 summarizes the described
sample distribution. For all these samples, we obtained the DNA
methylation fingerprints defined by the status of 1505 CpG sites
located from 1500 bp to +500 bp around the transcription start
sites (Supplemental Fig. 2) of 808 selected genes using the Golden-
Gate DNA methylation BeadArray (Illumina, Inc.) assay (Bibikova
et al. 2006; Byun et al. 2009; Christensen et al. 2009). The panel of
genes includes oncogenes and tumor-suppressor genes, imprinted
genes, genes involved in various signaling pathways, and those
responsible for DNA repair, cell cycle control, metastasis, differ-
entiation, and apoptosis (Bibikova et al. 2006; Byun et al. 2009;
Christensen et al. 2009). Sixty-nine percent (n = 1044) of the 1505
CpG sites studied are located within a canonical CpG island (Takai
and Jones 2002), while 31% (n = 461) are situated outside CpG is-
lands (Supplemental Fig. 2). All human chromosomes, except the Y
chromosome, are represented among the CpG sites analyzed (Sup-
plemental Fig. 2). CpG sites in ‘‘CpG island shores,’’ regions of
comparatively low CpG density within 2 kb of CpG islands, are not
printed in the array used, and their biological relevance has already
been extensively studied (Doi et al. 2009; Irizarry et al. 2009). Briefly,
in our case, four probes were designed for each CpG site: two allele-
specific oligos (ASOs) and two locus-specific oligos (LSOs). Each
ASO–LSO oligo pair corresponded to either the methylated or
unmethylated state of the CpG site. After bisulfite treatment con-
version, the remaining assay steps were identical to those of the
GoldenGate genotyping assay using Illumina-supplied reagents and
conditions, and the arrays were imaged using a BeadArray Reader
(Illumina, Inc.). Each methylation data point was represented by
fluorescent signals from the M (methylated) and U (unmethylated)
alleles. Before analyzing the CpG methylation data, we excluded
possible sources of technical biases that could have influenced the
results. Every beta value in the GoldenGate platform is accompa-
nied by a detection P-value, and we observed that a threshold
P-value above 0.01 indicated unreliable beta values (130 CpGs).
X-chromosome CpG sites with female-specific DNA methylation
(Reik andLewis 2005)were also excluded (44CpGs). Finally, nineCpG
sites that were unmethylated in all normal and disease-associated
sampleswere also excluded. Using these filters, 1322CpGs proved to
be reliable and were used subsequently in the study. Further tech-
nical information is provided in the Supplemental Methods. The
precise DNAmethylation status of every CpG dinucleotide analyzed
in each of the 1628 samples studied is freely available by down-
loading from the NCBI Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) under accession number GSE28094.
DNA methylation fingerprint of human normal tissues
We analyzed first the DNA methylation fingerprints for 424 hu-
man normal tissues. Of the 424 normal tissues studied, only 1%
(n = 17) of CpGs (corresponding to 14 genes) were methylated in
all the samples studied (Supplemental Table 2). These exclusively
methylated CpG dinucleotides were preferentially located outside
CpG islands (82%; Fisher’s exact test, p = 1.973105). Conversely,
37% (n = 488) of the CpGs, corresponding to 359 59 ends of genes,
were exclusively unmethylated in every normal tissue studied
(Supplemental Table 3). These always-unmethylated CpG dinu-
cleotides were almost exclusively located within CpG islands
(98%; Fisher’s exact test, p = 2.2031085) and were associated with
housekeeping expression genes (Fisher’s exact test, p = 1.133104)
(Supplemental Methods). Most importantly, significant differential
DNA methylation (Kruskal-Wallis rank-sum test, p < 2.2131016)
was encountered between different normal samples of 511
CpG dinucleotides using elastic net classifiers, which enabled their
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distinction on the basis of tissue type using an unsupervised hierar-
chical clustering approach (Fig. 1A). The 511 CpG sites described
correspond to 359 genes and, providing further validation to the
data, 220 genes (61%; 220) and 137 (38%) were previously iden-
tified as genes with tissue-specific DNA methylation using the
same 1505 CpG platform (Byun et al. 2009) or a 27,000-CpG
microarray (Nagae et al. 2011), respectively. Illustrative examples
of genes found in the three sets, and also confirmed by bisulfite
genomic sequencing in another independent study (Eckhardt et al.
2006), include TBX1 (T-box 1), OSM (oncostatin M), and GP1BB
(glycoprotein Ib [platelet] beta polypeptide). Examples of tissue-
specific CpG methylation further validated by pyrosequencing
(‘‘technical replicates’’) are shown in Supplemental Figure 3.
For our 359 genes with tissue-type-specific CpGmethylation,
their expression patterns in the 21 normal tissues are known (GEO
Expression Omnibus, GEO; http://www.ncbi.nlm.nih.gov/geo/)
(Supplemental Methods). Unsupervised clustering analysis of the
expression of these 359 genes discriminates each normal tissue
type, as the CpG methylation did, reinforcing the association be-
tween DNA methylation and transcriptional silencing of the neigh-
boring gene for these targets (Supplemental Fig. 3). Strikingly, the
CpG sites for which methylation status was the most valuable for
discriminating between tissue types were those located in non-
CpG-island 59 ends (Fisher’s exact test, p = 5.8531049). These
data support the long-standing hypothesis that most housekeep-
ing genes contain CpG islands around their transcription start
sites, while half of the tissue-specific genes have a CpG island at
their 59 ends, and the other half are 59-CpG-poor (Illingworth and
Bird 2009). The top-scoring genes with defined organ-specific
DNA methylation are listed in Supplemental Table 4. The tissue-
type-specific DNA methylation patterns, which are in line with
previous observations in humans (Eckhardt et al. 2006; Shen et al.
2007; Byun et al. 2009; Christensen et al. 2009), also match the
developmental layers in which the tissues originated (endoderm,
mesoderm, or ectoderm) (Fig. 1A), implying the existence of germ-
layer-specific DNA methylation (Sakamoto et al. 2007). Interest-
ingly, 49 CpG sites corresponding to 26 imprinted genes were also
included in the assay (Supplemental Fig. 4). We observed that CpG
sites located outside differentially methylated regions (DMRs)
(Dindot et al. 2009; Monk 2010) behaved like the CpGs of non-
imprinted genes in normal tissues: CpGs located within and out-
side CpG islands were unmethylated and methylated, respectively
(Supplemental Fig. 4). However, CpGs within DMRs were 50%
methylated in all normal tissue types studied (Supplemental Fig. 4).
Within the same tissue type, interindividual DNA methyla-
tion differences wereminimal. For example, the DNAmethylation
Figure 1. DNAmethylation fingerprints for human normal tissues. (A) Unsupervised hierarchical clustering and heatmap including CpG dinucleotides
with differential DNA methylation encountered between different normal primary samples. Tissue type and development layers are displayed in the
different colors indicated in the figure legends. Average methylation values are displayed from 0 (green) to 1 (red). (B) Deviation plot for the 1322 CpG
sites studied in leukocyte samples showing that little CpGmethylation heterogeneity (yellow area) occurs overall at CpG sites within CpG islands (red lines
in the track below), while more differences in CpG methylation are observed outside CpG islands (blue lines in the track below). (C ) Unsupervised
hierarchical clustering and heatmap including sets of genes with high correlation values between hypomethylation (up) and hypermethylation (down)
with aging. (D) Unsupervised hierarchical clustering and heatmap showing the DNA methylation patterns of embryonic and adult stem cells, comparing
them with corresponding normal and differentiated tissues (muscle, bone, and neuron; and muscle and brain, respectively).
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deviation plot for the 1322 CpG sites studied in leukocyte samples
from 180 healthy donors showed little heterogeneity (Fig. 1B).
However, it is interesting to note that the main DNA methylation
differences between individuals occurred at CpG sites located out-
side CpG islands in comparison to CpG-island-associated CpG di-
nucleotides (Wilcoxon test, p = 3.5231039) (Fig. 1B). One in-
teresting issue concerned the putative impact of aging on the DNA
methylation patterns of normal tissues in humans (Christensen
et al. 2009; Rakyan et al. 2010; Teschendorff et al. 2010) and mice
(Maegawa et al. 2010). Our analysis of the leukocyte samples from
the 180 healthy donors (Fig. 1B) revealed sets of genes that were
significantly hypermethylated (n = 43) or hypomethylated (n = 25)
during the normal aging process (Fig. 1C; Supplemental Table 5).
Examples of age-specific CpG methylation further validated by
pyrosequencing are shown in Supplemental Figure 4. It is encour-
aging to note that there are genes with age-related methylation
found in our study that were also identified in the mentioned pre-
vious reports using the same 1505 CpG platform (Christensen et al.
2009) or the 27,000 CpG microarray (Rakyan et al. 2010; Teschen-
dorff et al. 2010). Among these, we can underline for the age-
hypermethylated genes MYOD1 (myogenic differentiation 1), and
for the age-hypomethylated genes representative examples include
NOD2 (also known as CARD15, caspase recruitment domain-con-
taining protein 15), ACVR1 (activin A receptor type I), and SOD3
(SuperoxideDismutase 3). Furthermore,we also found that theCpG
hypermethylation events in aging were significantly more likely to
occur in the promoters of those genes with enriched Polycomb
occupancy (Fisher’s exact test, p = 3.833108; permutation P-value=
0.0014) and the presence of the bivalent histone domain (3mK4H3
+ 3mK27H3) (Fisher’s exact test, p = 9.033104; permutation P-
value = 0.0354) in embryonic stem cells (Supplemental Fig. 4), as
was recently suggested (Rakyan et al. 2010; Teschendorff et al. 2010).
In addition to the tissue-type-specific DNA methylation pat-
terns, one group of normal cells had distinctive DNA methylation
profiles: embryonic and adult stem cells (Fig. 1D). Adult and em-
bryonic stem cells both had DNAmethylation fingerprints that did
not resemble any of the differentiated primary normal tissues
studied (Fig. 1D). Furthermore, we confirmed that the previously
studied samples from multipotent adult stem cells (Aranda et al.
2009) had different DNAmethylation fingerprints frompluripotent
embryonic stemcells (Fig. 1D).Herein, wewent further to show that
induction of differentiation of both types of stem cells through
different lineages produced DNA methylation fingerprints that re-
sembled those present in the corresponding normal differentiated
tissues, such as muscle or neuron (Fig. 1D). Interestingly, in vitro–
differentiatedmaterial from adult and embryonic stem cells did not
completely recapitulate the DNA methylation patterns present in
the corresponding primary differentiated tissues, and there were
always deficiently methylated CpG sites. Supplemental Table 6 pro-
vides examples of these in muscle and neuronal tissues. Supple-
mental Figure 5 shows examples of tissue-specific CpGmethylation,
unachieved upon in vitro differentiation of stem cells and validated
by pyrosequencing analysis.
DNA methylation fingerprint of human cancer
We next studied the DNA methylation fingerprints for 1054 hu-
man tumorigenesis samples. Genetic and epigenetic alterations
both contribute to cancer initiation and progression (Jones and
Baylin 2007; Esteller 2008). One of the first epigenetic alterations
found in human cancer was the global low level of DNA methyla-
tion in tumors compared with healthy tissue counterparts. Global
DNA hypomethylation is accompanied by hypermethylation of
CpG islands at specific promoter regions. Nowadays, hyper-
methylation of the CpG islands in the promoter regions of tumor-
suppressor genes is also recognized as a major event in the origin of
many cancers (Jones and Baylin 2007; Esteller 2008). Tumor-sup-
pressor genes disrupted by DNA methylation-associated tran-
scriptional silencing in sporadic tumors include the retinoblas-
toma tumor suppressor gene (RB1), VHL (associated with von
Hippel-Lindau disease), the cell cycle inhibitor CDKN2A (also
known as p16INK4a),MLH1 (a homolog of Escherichia coli mutl), and
BRCA1 (breast-cancer susceptibility gene 1) (Jones and Baylin
2007; Esteller 2008). Using candidate gene approaches and early
epigenomics technologies, a CpG-island hypermethylation profile
of human primary tumors emerged that suggested that a defining
DNA hypermethylome could be assigned to each tumor type
(Costello et al. 2000; Esteller et al. 2001; Ballestar and Esteller
2008). Herein, we have analyzed the DNA methylation finger-
prints of 1054 human tumorigenesis samples, including 855
primary malignancies (611 solid tumors from 19 tissue types
and 244 hematological malignancies), 50 metastatic lesions, 25
premalignant lesions, 82 cancer cell lines, and 42 cancers of
unknown primary origin (CUPs) (Supplemental Table 1). The
DNA methylation map that emerges shows a tumor-type-specific
profile characterized by the progressive gain of CpG methylation
within CpG-island-associated promoters and a cumulative loss of
CpG methylation outside CpG islands in the different steps of
tumorigenesis.
First, unsupervised clustering of the DNA methylation pro-
files obtained from the 855 primary tumors demonstrated that
each type of malignancy had its own aberrant DNA methylation
landscape (Fig. 2A). From a quantitative standpoint, 1003 CpG
sites (76% of the 1322 validated CpGs) had significantly different
methylation levels between tumor types (Kruskal-Wallis rank-sum
test, p < 2.231016). The distinction of primary tumors by their
tissue of origin was maintained even when we subtracted the tis-
sue-type-specific DNA methylation described above (511 CpG
sites) (Supplemental Table 4) from the analysis of the DNA meth-
ylation profiles for each normal tissue (Fig. 2B). Comparing each
tumor type with its corresponding normal tissue, 729 CpG sites
(55% of the 1322 CpGs) showed differential DNA methylation.
Using these tumor/normal differentially methylated CpG sites,
overall human primary tumors were characterized by increased
levels of CpG dinucleotide methylation: 68% (n = 496) were
hypermethylated and 32% (n = 233) were hypomethylated (t-test,
p = 3.5213105) (Fig. 2C). Most importantly, the location of these
DNA methylation events differed: CpG dinucleotide hyper-
methylation occurred within CpG islands (78%), while CpG
hypomethylation was present in 59 ends of non-CpG-island genes
(78%; Fisher’s exact test, p = 2.5931047; permutation P-value <
0.001) (Fig. 2C). A DNA methylation deviation plot for the 1322
CpG sites studied in all normal primary tissues (n = 390) versus all
primary tumors (n = 855) shows the hypermethylated CpG sites
within CpG islands and hypomethylated CpG sites outside CpG
islands observed in the malignancies (Fig. 2C) (Paired Wilcoxon
test, p < 2.231016). CpG sites with cancer-specific differential
methylation according to tumor type in comparison with their
corresponding normal tissue are provided in Supplemental Table 7.
Examples of cancer-type-specific CpG methylation further vali-
dated by pyrosequencing are shown in Supplemental Figure 6.
Those CpG sites with highly specific methylation changes occur-
ring only in one tumor type are shown in Supplemental Table 8.
Interestingly, we also confirmed the previous observation (Ohm
Fernandez et al.
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et al. 2007; Schlesinger et al. 2007;Widschwendter et al. 2007) that
the CpG hypermethylation events in cancer were significantly
more likely to occur in the promoters of those genes with enriched
Polycomb occupancy (Fisher’s exact test, p = 5.033106; permu-
tation P-value = 0.0012) and the presence of bivalent histone do-
mains (3mK4H3 + 3mK27H3) (Fisher’s exact test, p = 5.973104;
permutation P-value = 0.0278) in embryonic stem cells (Supple-
mental Fig. 6). We also found evidence to reinforce the link be-
tween the 59-end CpG methylation and transcriptional silencing
(Jones and Baylin 2007; Esteller 2008) by developing expression
microarray studies (Supplemental Methods) in the 19 primary
colorectal tumors from which we had obtained the DNA methyl-
ation profiles. We observed that the median expression of all the
CpG hypermethylation-associated genes was significantly lower
than in those CpG hypomethylation-linked genes (Kruskal-Wallis
test, p = 1.563108) (Supplemental Fig. 6).
For our largest set of samples with paired normal–tumor tis-
sues from the same patient (41 cases of colorectal cancer), we ob-
served that of the 1322 CpG sites studied, CpG dinucleotides
within CpG-island promoters became significantly more DNA-
methylated in 79%of cases (34 of 43 normal/tumor pairs;Wilcoxon
test, p = 2.473107), while CpGs located in non-CpG-island pro-
moters more commonly underwent DNA hypomethylation events,
in 51% of cases (22 of 43 normal/tumor pairs; Wilcoxon test, p =
0.001). If we consider the colorectal tumor population as a whole,
in 68% of cases (28 of 41) the primary malignancy gained CpG
dinucleotide methylation within promoter CpG islands and non-
CpG-island promoters, while in 15% of tumors (six of 41) the gain
of CpG island methylation occurred in a context of loss of pro-
moter non-CpG-islandmethylation (Fig. 3A). Interestingly, 17%of
cases (seven of 41) featured a loss of methylation in both promoter
CpG islands and non-CpG-island promoters (Fig. 3A). Thus, the
presence of hypermethylation of promoter CpG islands appears
to be a common hallmark of human tumors, but there are subsets
of cancers that present other DNA methylation profiles at pro-
moter CpG sites that suggest additional and complex aberrant
DNA methylation pathways in tumorigenesis. For example, the
possibility that DNA hypomethylation events at CpGs located in
non-CpG-island promoters, typical of genes with restricted tissue-
specific expression (Illingworth and Bird 2009), can cause a loss of
cellular identity in transformed cells is worth further investigation.
As cancer cell lines are amajor tool in biomedical research, we
next examined how the DNA methylation profiles of cell lines
differ from those of the primary tumor types. The analyses of the
DNA methylation fingerprints of 82 human cancer cell lines rep-
resenting 14 tumor types (Supplemental Table 1) showed that, over-
all, they preserved their original cancer-type-specific profile and
underwent an increase in the levels of CpG dinucleotide meth-
Figure 2. DNA methylation fingerprint of human cancer. (A) Unsupervised hierarchical clustering and heatmap showing distinction of primary tumor
DNA methylation fingerprints according to the tissue of origin. (B) Unsupervised hierarchical clustering and heatmap of primary tumors excluding CpG
sites with tissue-specific methylation. (C, above) Pie charts displaying the percentage of hypermethylated CpG sites (red) and hypomethylated CpG sites
(green) in humanmalignancies, and their distribution in CpG islands (CGI in red) and outside CpG islands (non-CGI in blue). (Below) Deviation plot for the
1322 CpG sites showing the great methylation heterogeneity (yellow area) of primary tumors in comparison with normal primary tissues.
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ylation in comparison with the corresponding normal tissues
(Paired Wilcoxon test, p < 2.231016) (Supplemental Fig. 7), as
occurswithmost primary tumors. Examples of CpGmethylation in
cancer cell lines further validated by pyrosequencing are shown in
Supplemental Figure 7. In the same line as primary malignancies,
the hypermethylated CpG sites in cancer cell lines occurred sig-
nificantly more often within CpG islands (Supplemental Fig. 7),
while CpG hypomethylation events mainly happened around
transcription start sites that did not contain a CpG island (Paired
Wilcoxon test, p < 2.231016) (Supplemental Fig. 7). However,
there were qualitative and quantitative differences. First, human
cancer cell lines had significantly greater hypermethylation of
promoter CpG islands and non-CpG-island promoters (Paired
Wilcoxon test, p < 2.231016) (Supplemental Fig. 7). At this stage,
we cannot distinguish whether these greater changes are associ-
ated with the in vitro growth of these cells over many years, or if
the DNAmethylation changes were more detectable because there
was no contaminating normal tissue, as is the case in primary tu-
mors. Second, there are a set of specific CpG sites that only undergo
differential DNA methylation in cancer cell lines (Supplemental
Table 9), which enable them to be classified into a distinct clus-
tering arm in the unsupervised analysis (Fig. 3B). We further tested
the association between hypermethylated CpGs at the 59 ends
and transcriptional silencing of the corresponding gene by treat-
ing five cancer cell lines (SW480, HN-011A, HN-011B, IGR37, and
IGR39)with theDNAdemethylating agent 59-aza-29-deoxycytidine,
followed by gene expression microarray analysis (Supplemental
Methods). We observed that while genes with associated hyper-
methylated CpGs had a low median expression compared with
their corresponding normal tissues, upon treatment with the hy-
pomethylating agent, their expressions were restored (Supplemen-
tal Fig. 8).
The comprehensive collection of human tumorigenesis
samples studied here allowed us to address two other interesting
aspects of cancer epigenetics: timing and progression. For genetic
changes, it is well known that there is an accumulation of genetic
events that drive the carcinogenesis process from the healthy tis-
sue to early premalignant lesions and finally to established full-
blown tumors and metastasis, as exemplified by colorectal tumori-
genesis (Fearon and Vogelstein 1990). Candidate gene approaches
Figure 3. Scenarios of DNA methylation changes in human tumorigenesis. (A) Bart plot showing the CpG hypermethylation or hypomethylation
changes observed when comparing paired normal–tumor tissues from the same colorectal cancer patient. They can be distinguished if the methylation
change occurs in CpG island (CGI) or non-CpG island (non-CGI)–associated CpG. (B) Unsupervised hierarchical clustering and heatmap including a set of
specific CpG sites that undergo differential DNA methylation only in cancer cell lines. (C ) Deviation plot for the 1322 CpG sites shows greater CpG
methylation heterogeneity (yellow area) in established tumors (colon, breast, and endometrial cancers) than in their corresponding premalignant lesions.
(D) DNAmethylation unsupervised clustering analyses and heatmap of primary tumors, local liver metastases, and distant brain metastases from the same
colorectal cancer patient. A CpG methylation-specific pattern for brain metastases (green lanes) is observed. (E) CpG methylation prediction heatmap
showing the CUP classification to a specific tumor type.
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and limited epigenomics strategies have also indicated that this
could be a pathway leading to aberrant DNA methylation changes
(Fraga et al. 2004). Our analysis of the DNA methylation signatures
in progressive samples of three different tumorigenesis pathways
(colon, breast, and endometrial cancers) demonstrated the in-
creasing degree of CpG dinucleotide methylation within promoter
CpG islands and a loss of CpG methylation outside CpG islands
in consecutive steps (Fig. 3C). The DNAmethylation deviation plot
for the 1322 CpG sites in colorectal adenomas versus primary co-
lorectal tumors, breast hyperplasias versus primary breast tumors,
and endometrial hyperplasias versus primary endometrial carcino-
mas demonstrated that the full-blown tumors had significantly
greater hypermethylation of promoter CpG islands in association
with the loss of CpG methylation in non-CpG islands than their
corresponding premalignant lesions (Paired Wilcoxon test, p <
2.231016) (Fig. 3C).Most importantly, for colorectal tumorswhere
we had DNA from brain metastasis available, these distant metas-
tasis lesions achieved higher levels of promoter CpG-island hyper-
methylation and lower levels of non-CpG-island methylation
than the primary colon malignancies (Paired Wilcoxon test, p <
2.231016), suggesting that these pathological entities are the final
stages of the disease. In fact, the DNA methylation unsupervised
clustering analyses of primary tumors, local liver metastases, and
distant brain metastases from the same colorectal cancer patient
showed that there were specific hypermethylated CpGs in the brain
metastases (Fig. 3D; Supplemental Table 10). Examples of specific
CpG methylation in the brain metastasis of colorectal tumors vali-
dated bypyrosequencing are shown in Supplemental Figure 8.Ninety
percent of cancer deaths are attributable to the development of me-
tastasis (Mehlen and Puisieux 2006), thus these findings might have
a translational value for the prediction of the metastatic capacity of
a particular tumor, as has recently been shown for hypermethylated
microRNA loci, and it might be a useful molecular marker in the de-
cision process for medical and surgical intervention in the disease.
TheDNAmethylation fingerprints of human cancer obtained
in our study can also provide additional important molecular di-
agnostic and prognostic biomarkers for the management of neo-
plasias. One example we have assessed is the case of the clinical
entities classified as cancers of unknown primary origin (CUPs).
These are patients who present metastatic diseases for which the
primary site cannot be found despite standard investigation. The
median survival in randomized studies of these patients is ex-
tremely poor (Abbruzzese et al. 1995), but if it were possible to
predict the primary tumor site, the patient could be treated with
a site-specific program, potentially resulting in better survival than
that provided by non-specific treatment, for which the current
median is only 7 mo (Greco and Pavlidis 2009). We have analyzed
the DNA methylation fingerprints of 42 CUPs and compared
the DNA methylation landscapes obtained with those from the
aforementioned human malignancy collection where the original
tissue type was known. We were able to assign a given tumor type
for these CUPs in 69% (29 of 42) of cases using L1-regularized lo-
gistic regression with misclassification (R, version 2.10) to create
a prediction heatmap (Fig. 3E). A proposed foster primary in these
29 cases was also achieved by conventional clustering analysis
(Supplemental Fig. 8). Most importantly, the tumor type predic-
tion of the CUPs based on the DNAmethylation analyses was fully
confirmed in 78% of cases (seven of nine) for which detailed
pathological analysis developed at a later stage in a blind fashion
was able to provide a diagnosis. We might also conclude that the
remaining 31% (13 of 42) of the studied CUP cases did not repre-
sent any of the 19 tumor types included in our analysis (Supple-
mental Table 1). The three most common tumor types present in
the DNAmethylation-assigned CUPs were colorectal cancer (34%,
10 of 29), non-small-cell lung cancer (17%, five of 29), and breast
tumors (17%, five of 29). These cases are particularly interesting
because the introduction of targeted therapies, such as treatment
with epidermal growth factor receptor (EGFR) antibodies in co-
lorectal cancer, small-molecule inhibitors for EGFR mutations in
lung adenocarcinoma, and more personalized chemotherapy op-
tions for breast cancer as a function of the hormonal and ERBB2
receptor status have improved the outcome of these patients
(Harris andMcCormick 2010). Thus, it is tempting to propose that
the prediction of a foster primary site for CUPs based on the DNA
methylation profiles might identify a more specific treatment
regimen for these patients that would improve their quality of life
and survival.
DNA methylation fingerprint of non-cancerous
human diseases
We also analyzed the DNA methylation profiles for 150 non-
cancerous human diseases. Although most of the aberrant DNA
methylation patterns described in human disease have been re-
ported for cancer, there is no reason to believe that disrupted DNA
methylation signatures are not present, and might drive other
common human diseases (Feinberg 2007), such as neurological
(Urdinguio et al. 2009), cardiovascular (Gluckman et al. 2009),
and autoimmune (Richardson 2007) disorders. The data on DNA
methylation changes outside cancer are still scarce, but this could
be more likely because of the small number of studies devoted to
these pathologies than because DNA methylation disruption is
genuinely of little importance in the origin and progression of
these diseases. To address this issue, we analyzed the correspond-
ing target tissues of 150 non-cancerous human diseases, including
cerebral cortex lesions from Alzheimer’s (n = 11) and dementia
with Lewy bodies (n = 13), atherosclerotic lesions from the aorta
(n = 18), skeletal muscle frommyopathies (n = 17), leukocytes from
autoimmune disorders (n = 21), and other non-tumoral diseases
and tissues (n = 70) (Supplemental Table 1).
One of the most striking observations was that the described
non-tumoral diseases in an unsupervised clustering had a distinct
DNA methylation pattern, even if the tissue-specific CpG meth-
ylated sites were not included in the analysis (Fig. 4A). In the cases
of dementia with Lewy bodies (Fig. 4B) and systemic lupus erythe-
matosus (Supplemental Fig. 9), the DNA methylation patterns
obtained from the 1322 CpG sites distinguished them from their
corresponding normal tissues. Most importantly, the correspond-
ing distinctions between brain samples of dementia with Lewy
bodies versus normal brain and leukocytes of lupus patients versus
healthy donor samples were exclusively associated with CpG
hypomethylation events in the disease tissue (Supplemental Table
11). Examples of dementia with Lewy bodies–specific CpG hypo-
methylation further validated by pyrosequencing are shown in
Supplemental Figure 9. Interestingly, the sequestration of DNA
methyltransferase 1 (DNMT1) in the cytoplasm of neurons from
patients affected by dementia with Lewy bodies has been recently
described (Desplats et al. 2011), a mechanism that could explain
the hypomethylation events observed in this disease using our
approach. Related to the lupus patients, it is noteworthy to con-
sider that these samples were also previously analyzed using the
same 1505 CpG array to search for DNA methylation differences
betweenmonozygotic twins ( Javierre et al. 2010). Herein, theywere
studied in a more stringent manner because they were compared to
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a new large set of normal leukocytes (n = 180) and with a higher
cutoff value for methylation. Among the lupus-common genes
derived from both studies, it is relevant to mention the hypo-
methylation event targeting PI3 (Proteinase Inhibitor 3), a protein
that has been involved in psoriasis with an autoimmune compo-
nent (Tjabringa et al. 2008). With the CpG array used, we were
unable to find any significant difference between brain samples
from Alzheimer’s patients (Fig. 4B), aorta samples from athero-
sclerotic lesions (Supplemental Fig. 9), myopathies (data not
shown), and their respective normal tissues.
The DNA methylation profiles obtained from the aforemen-
tioned non-cancer disorders were distinct from those observed in
tumors originating from the same cell type. Dementia with Lewy
bodies’ patients had CpG-site methylation patterns that distin-
guished them not only from normal brain (Fig. 4B), but also from
neuroectodermal tumors, such as glioma and neuroblastoma
(Fig. 4C). Interestingly, brain samples from dementia with Lewy
bodies’ patients were closer, from a DNA methylation fingerprint
perspective, to neuroblastomas than to gliomas (Fig. 4C), a char-
acteristic that might be associated with the different cell biology of
the disorders. Although in dementia associated with Alzheimer’s
disease there is a high grade of neuronal cell death that causes an
over-representation of glia cells in the studied samples (gliosis)
( Jellinger and Stadelmann 2001; Teaktong et al. 2003), in the de-
mentia with Lewy bodies’ brain there is not suchmassive neuronal
cell death (Jellinger and Stadelmann 2001; Teaktong et al. 2003),
and the DNA methylation profiles observed resembled those
found in neuron-enriched samples, such as neuroblastomas. In
this regard, the existence of different DNA methylation patterns
among brain regions with different cell composition has also been
suggested (Ladd-Acosta et al. 2007). Distinct DNA methylation
profiles for non-malignant and malignant disorders originating
from the same cell type also occur for leukocytes of lupus patients
displaying DNA methylation profiles that are different from
those present in healthy donors or in leukemias (Supplemental
Fig. 9).
Overall, these findings suggest that few specific DNA meth-
ylation changes in non-cancerous human diseases could be re-
sponsible for the observed phenotypes of these entities; they
nevertheless merit further attention. Most importantly, the spe-
cific DNA methylation changes found in the described disorders
occurred in clear contrast to human cancer, where the DNA meth-
ylation profile undergoes a wide-ranging, global change character-
ized by the gain of promoter CpG-island methylation and loss of
non-CpG-island methylation. These results underlie the multifac-
torial nature of human cancer that involves epigenetic ‘‘hits’’ in
almost all known cellular pathways, exemplified by the aberrant
DNA methylation fingerprints obtained here.
Discussion
Disruption of the DNA methylation patterns is emerging as a
common feature of human disease (Portela and Esteller 2010),
where cancer is the disorder on which most of the studies have
been focused (Jones and Baylin 2007; Esteller 2008). From the
initial studies looking at a single locus, we have now available a
wide range of epigenomics techniques to study multiple CpG sites
in the human genome. In addition to methods that isolate meth-
ylated fractions of the genome bymethylation-sensitive restriction
(Lippman et al. 2005; Irizarry et al. 2008), immunoprecipitation
with amethylcytosine (Weber et al. 2005, 2007; Keshet et al. 2006;
Down et al. 2008) or methyl-CpG binding domain antibody
(Ballestar et al. 2003; Rauch et al. 2009) and the genome-wide bi-
sulfite genomic sequencing approaches (Li et al. 2010; Lister et al.
2009), it is worthwhile to highlight DNA methylation bead micro-
arrays (Bibikova et al. 2006). This approach has the advantage that
it can be used in a common standard manner by different labora-
tories around the world with similar bioinformatics packages, and
Figure 4. DNA methylation fingerprint in non-tumoral human diseases. (A) Unsupervised hierarchical clustering and heatmap of several non-tumoral
diseases showing distinct DNA methylation profiles. (B) Unsupervised hierarchical clustering and heatmap showing significant differences between the
DNA methylation patterns of dementia with Lewy bodies and normal controls. The CpG methylation platform used was unable to detect significant
differences in the case of Alzheimer’s versus healthy brain tissues. (C ) Unsupervised hierarchical clustering and heatmap showing differences between
dementia with Lewy bodies and neuroectodermal tumors (glioma and neuroblastoma).
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the raw data can be user-friendly, deposited, and shared. Herein,
using the first version of the DNA methylation bead microarray,
which included 1505 CpG sites corresponding to 808 genes, we
have studied the largest collection of human samples to date, 1628,
that included 424 normal tissues, 1054 tumorigenic samples, and
150 non-cancerous disorders. Our data provide new clues about
the DNA methylation profiles present in normal and disease-
associated tissues and also expand and confirm previous reports in
this area obtained using the same platform (Aranda et al. 2009;
Byun et al. 2009; Christensen et al. 2009; Javierre et al. 2010) or
a second DNA methylation bead microarray that includes 27,000
CpG sites (Rakyan et al. 2010; Teschendorff et al. 2010; Nagae et al.
2011). In normal cells, the derived picture reinforces the role of
methylation in non-CpG-island 59 ends to determine tissue-spe-
cific expression, the shift in the DNAmethylation landscape from
pluripotent to differentiated cells, and the existence of a DNA
methylation drift associated with aging. For transformed cells, the
study demonstrates that tumors undergo mostly a progressive
CpG hypermethylation within CpG islands, while CpG hypo-
methylation occurs in 59 ends of non-CpG-island genes. For other
human disorders, such as dementia with Lewy bodies and lupus,
we show that they also possess a particular DNA methylation fin-
gerprinting that is mainly characterized by CpG hypomethylation
events. One extra value of the present study is that it not only
provides new DNA methylation markers for all the described
normal and pathological settings, but it also validates previous
results in aging (Christensen et al. 2009; Rakyan et al. 2010;
Teschendorff et al. 2010), tissue specificity (Eckhardt et al. 2006;
Byun et al. 2009; Christensen et al. 2009), or lupus ( Javierre et al.
2010). Furthermore, the deposited data for the 1628 human
samples (http://www.ncbi.nlm.nih.gov/geo; accession number
GSE28094) can be a value resource for further biocomputational
and meta-analysis studies.
Overall, the goal of the research described here was to ex-
amine human DNA methylation profiles comprehensively from
an extremely extensive range of samples that covers physiological
changes (across different tissue types, sex, age, geography, differ-
entiation vs. stemness, primary vs. cell culture, etc.) and human
diseases (cancer and common non-tumoral diseases, such as neu-
rological, cardiovascular, and autoimmune disorders). The results
obtained indicate that different DNAmethylation fingerprints are
observed in most of the described conditions, cancer samples be-
ing the result of the most extreme type of DNA methylation
change observed, in which a profile of an increased degree of CpG
dinucleotide methylation within promoter CpG islands and a loss
of CpGmethylation outside CpG islands is a commonhallmark, as
described above. A DNAmethylation signature that becomesmore
distorted as the disease progresses can provide potentially relevant
clues for improving diseasemanagement for these patients, such as
we have demonstrated for the CUP cases.
We would like to underscore the relevance of the CUP DNA
methylation fingerprints. Despite the increasing sophistication
in the diagnostic tools for malignancies, deaths due to CUP were
estimated to be 45,230 in 2007 in the United States (American
Cancer Society 2007). CUPs have an incidence of 6% among all
malignancies, and in 25% of cases, the primary site cannot be
identified even upon postmortem examination (American Cancer
Society 2007). The inability to identify the primary site of the
cancer and the impossibility to provide the right treatment has
a large impact on the expected clinical outcome of these patients.
Herein, the acquisition of DNA methylation fingerprints for 1054
tumorigenic samples allowed the classification according to cancer
type of almost 70% of the studied CUPs, a result that can make
a difference in the prognosis of these patients. This is just an ex-
ample of the possible translational use of the DNA methylation
profiles provided. Other uses might follow, and they will require
further development, such as our finding of a distinct DNA meth-
ylation fingerprint between local liver metastases and distant brain
metastases derived from colorectal tumors that might suggest the
use of DNAmethylation patterns to predict themetastatic spectrum
of a given cancer. We would also like to highlight another prom-
ising step in the clinical-benefits direction by the recent finding of
27,000 CpG-site DNA methylation profiles in blood that are as-
sociated with bladder cancer risk (Marsit et al. 2011).
One obvious limitation of our approach is the level of reso-
lution, since only 1505CpG siteswere interrogated. The increasing
number of studies developed and under way using the 27,000-
CpG-site platform and the future reports using the new 450K-CpG-
site microarray will be useful to further validate and complement
the DNAmethylation profiles obtained.We can only imagine how
the firm, automatic, and affordable establishment of whole-genome
sequencing of complete human DNA methylomes (Lister et al.
2009; Li et al. 2010) will yield further knowledge about the role
of DNAmethylation in cellular identity and its loss in disease. Even
so, the 1628 DNA methylation fingerprints described herein, and
displayed by tissue type and disease in Figure 5, are a promising
starting point for understanding the variation of human DNA
methylation over a range of normal and pathological conditions.
Methods
Filtering of probes and samples
Although the GoldenGate Assay by Illumina is an established,
highly reproduciblemethod for DNAmethylation detection, there
is currently no standard procedure for post-filtering of probes and
samples commonly used. Before analyzing the methylation data,
we explored several ways of excluding possible sources of bio-
logical and technical biases that could have affected and improved
the accuracy of the results. Every beta value in the GoldenGate
platform is accompanied by a detection P-value. We based the
criteria of filtering on these P-values reported by the assay. We
examined two aspects of filtering out probes and samples based on
the detection P-values, selecting a threshold and a cutoff. Our
analyses indicated that a threshold value of 0.01 allows a clear
distinction to bemade between reliable and unreliable beta values.
We selected the cutoff value as 5%. Following this criterion, we first
removed all probes with detection P-values >0.01 in 5% or more
of the samples. As a second step, we removed all samples with
detection P-values >0.01 in 5%ormore of their (remaining) probes.
In total, 130 probes and 87 samples were removed. We also
checked for and removed consistently unmethylated and meth-
ylated probes. We ignored all cell line samples and focused on the
remaining 1521 (primary tissue) samples. All probes exhibiting
a degree of methylation <0.25 for all primary tissue samples were
considered to be consistently unmethylated. Similarly, probeswith
a degree of methylation >0.75 for all primary tissue samples were
considered to be consistently methylated. We identified nine
consistently unmethylated probes; none of the probes fit our
definition for being consistently methylated. A known biological
factor is that one copy of chromosome X is methylated in women
(Reik and Lewis 2005), and, therefore, we decided to identify and
remove all probes with prominent gender-specific methylation, to
avoid hidden bias in the subsequent analyses. We considered the
set of 1271 samples with gender information; approximately half
of themwere female.We defined a probe to be gender-specific if (1)
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the probe showed a significant differential methylation between
the two sample groups, as determined by the Mann-Whitney
U-test with FDR correction; and (2) the mean methylation degrees
of females and males for this probe differed by at least 0.17 (a
limitation of the GoldenGate assay). After excluding 130 probes
that were not of sufficient quality, nine that were consistently
unmethylated and 44 that were gender-specific, 1322 probes were
available for further statistical analyses.
Analysis of differentially methylated probes
The large cohort of heterogeneous methylation profiles allows
us to identify differentially methylated probes under a variety of
scenarios. We analyzed different groups of tissue samples sepa-
rately (normal primary tissues, cancerous and non-cancerous dis-
eases, and cancer cell lines). We performed all statistical analyses
using the R environment for statistical computing (version 2.10;
http://www.R-project.org). Further explanation about detection of
differentially methylated probes and genes in each scenario, sta-
tistical analyses, and graphical representations are provided in the
Supplemental Methods.
Pyrosequencing
Pyrosequencing assays were designed to analyze and validate the
results obtained from the array under different scenarios. Sodium
bisulfite modification of 0.5 mg of genomic DNA isolated from
different tissues was carried out with the EZ DNA Methylation Kit
(Zymo Research Corporation) following the manufacturer’s pro-
tocol. Bisulfite-treated DNAwas eluted in 15-mL volumes with 2 mL
used for each PCR. The set of primers for PCR amplification and
sequencingwere designedwith a specific program (PyroMark assay
design version 2.0.01.15). Primer sequences were designed to hy-
bridize with CpG-free sites to ensure methylation-independent
amplification. PCR was performed with primers biotinylated to
convert the PCR product to single-stranded DNA templates. We
used the Vacuum Prep Tool (Biotage) to prepare single-stranded
PCR products according to the manufacturer’s instructions. Pyro-
sequencing reactions and quantification of methylation were
performed in a PyroMark Q24 System version 2.0.6 (QIAGEN).
Graphs ofmethylation values showbars identifyingCpG siteswith
values from 0% (white) to 100% (black).
Classification of CUPs
We used the advanced method L1-regularized logistic regression
with misclassification to classify the 42 CUP samples in our data
set into one of the known cancer types. By classifying a CUP, this
classifier gives probabilities (values between 0 and 1) for every
known cancer type. A CUP prediction heatmap was derived in R
(version 2.1.0) (Fig. 3E). The CUP samples were selected on the
basis of having a >30% probability of being ascribed to a specific
tumor type. The arrangement of the samples in the heatmap was
established by (1) ordering the tumor types by the number of CUPs
ascribed to each one; and (2) within each tumor type, ranking the
CUPs from the highest to lowest probability of ascription.
Expression data analysis
CEL files containing normal tissue gene expression data were
downloaded from the GEO database. Data series, samples, and anal-
ysis procedures are detailed in the Supplemental Methods.
Enrichment of PcG-marks and bivalent domains
in different methylation groups
The presence of PcG-marks and bivalent domains in different
methylation groups was compared using a Fisher’s exact test. In
addition to a Fisher’s exact test, we calculated permutation-based
P-values to account for interdependencies between the methyla-
tion states of different CpGs. Briefly, we performed a Fisher’s exact
test in 104 random reassignments of the studied samples and calcu-
lated the proportion of resulting P-values that is lower than or equal
to the originally obtained one. A genome-wide map of Polycomb
Figure 5. A DNAmethylation fingerprint of 1628 human samples. Unsupervised hierarchical clustering and heatmap of all the CpG methylation maps
obtained in the study, by tissue and disease type.
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target genes and 3mK4H3/3mK27H3-enriched genes in ESCs is
available as supplemental material of the articles by Lee et al.
(2006) and Pan et al. (2007), respectively.
Human cancer cell lines and expression upon
5-aza-29-deoxycytidine treatment
Five cancer cell lines—SW480 (colon), HN-011A and HN-011B
(esophagus), and IGR37 and IGR39 (melanoma)—were grown in
DMEMmediumsupplementedwith4mMglutamine, 10%FBSmand
100 units/mL penicillin/streptomycin at 37°C/5% CO2. All cell lines
were treatedwith 1mM5-aza-29-deoxycytidine (Sigma) for 72 h. Total
RNA was isolated from all cell lines before and after 5-aza-29-deoxy-
cytidine treatment by TRIzol extraction (Invitrogen), and 5 mg was
hybridized on the Human GeneChip U133 Plus 2.0 expression array
(Affymetrix). Expression data were normalized and analyzed follow-
ing the same procedures described in the Supplemental Methods.
Data access
The microarray data from this study have been submitted to the
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo) under accession number GSE28094.
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